Prime Medicine (PRME) EBT (2021 - 2026)
Prime Medicine posted quarterly EBT of -$49.6 million for Q1 2026, up 4.35% year-on-year from -$47.6 million in Q1 2025, and down 4.44% on a QoQ basis from -$47.5 million in Q4 2025.
Prime Medicine (PRME) has 6 years of EBT data on file, last reported at -$49.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 4.35% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at -$202.6 million (changed 0.22% YoY), and the FY2025 full-year result was -$204.2 million, down 4.25% from the prior year.
- EBT for Q1 2026 stood at -$49.6 million, down from -$47.5 million in the prior quarter.
- Across five years, EBT topped out at -$24.4 million in Q1 2022 and bottomed at -$65.6 million in Q4 2023.
- The 5-year median for EBT is -$47.5 million (2025), against an average of -$45.4 million.
- The widest annual swing landed in 2022, when EBT soared 35.85%; it then sank 74.4% in 2023.
- A 5-year view of EBT shows it stood at -$39.5 million in 2022, then tumbled by 66.32% to -$65.6 million in 2023, then jumped by 35.6% to -$42.3 million in 2024, then dropped by 12.42% to -$47.5 million in 2025, then retreated by 4.44% to -$49.6 million in 2026.
- The last three EBT figures came in at -$49.6 million (Q1 2026), -$47.5 million (Q4 2025), and -$52.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -49.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.63 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -52.83 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.46 Mn |
| Mar 31, 2024 | -45.63 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.82 Mn |
| Jun 30, 2023 | -42.35 Mn |
| Mar 31, 2023 | -39.60 Mn |
| Dec 31, 2022 | -39.47 Mn |
| Sep 30, 2022 | -29.14 Mn |
| Jun 30, 2022 | -29.79 Mn |
| Mar 31, 2022 | -24.37 Mn |
| Dec 31, 2021 | -61.53 Mn |
| Sep 30, 2021 | -18.78 Mn |